Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2022-01-04 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯第四届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of a company, detailing the convening and decisions made during the meeting, including approval of a proposal related to expected related-party transactions for the year 2022. It is a formal announcement of a board meeting decision rather than a full management report or financial statement. There is no indication of financial data, audit results, or regulatory filings beyond the meeting resolution. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2022-01-04 Chinese
普莱柯关于预计2022年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2022. It includes details about the nature, amounts, and approval procedures of these transactions, as well as the impact on the company. It is not a full financial report, audit report, or earnings release. It is a regulatory announcement about related party transactions, which is a common type of regulatory filing. The document length is under 5,000 characters and it does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS).
2022-01-04 Chinese
普莱柯第四届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 普莱柯生物工程股份有限公司. It details the convening of the fourth board's 23rd meeting, attendance, and voting results on specific agenda items such as related party transactions and guarantees for subsidiaries. There is no financial data, earnings information, or detailed report content. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a substantive announcement of board decisions.
2022-01-04 Chinese
普莱柯关于为全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing a guarantee for its wholly-owned subsidiary. It details the guarantee amount, the board's approval, the subsidiary's financial data, and the rationale behind the guarantee. There is no financial report or earnings data presented, nor is it a meeting presentation or voting result. The document is a regulatory announcement about a financing-related guarantee activity, which fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2022-01-04 Chinese
普莱柯独立董事关于第四届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding specific board meeting matters, including related party transactions and guarantees for subsidiaries. It references compliance with company law and internal regulations but does not contain financial statements or detailed financial data. The document is a formal opinion related to board decisions rather than a full management report or audit. It is not an announcement of voting results, nor a general regulatory filing. The content fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent director opinions on governance and company decisions.
2022-01-04 Chinese
普莱柯（南京）生物工程有限公司最近一期财务报表
Regulatory Filings Classification · 100% confidence The document text is extremely short (192 characters) and contains no substantive content, financial data, or any indication of report type. It only mentions '扫描全能王 创建' (which translates to 'Created by CamScanner'), and includes placeholders for omitted pictures. There is no mention of any report, announcement, or regulatory filing. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2022-01-04 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.